246results about How to "High biosecurity" patented technology

The invention discloses a grain specific promoter in the early stage of rice filling and application thereof, the promoter is named as proASP1, and the nucleotide sequence of the promoter is shown as SEQ ID NO: 1. The promoter has highly strict spatio-temporal expression specificity, the activation expression of the promoter is only limited in grains in the early stage of rice filling (4-12 days after flowering), especially the expression of genes is efficiently driven in endosperm and aleurone layers, and the expression is not leaked in other tissues such as roots, stems, leaves, leaf sheaths and glumes and grains in the middle and later stages of filling. The invention provides a basic and precious molecular tool for gene function research, quality improvement (such as protein and starch synthesis regulation) and bioreactor development in a key window period of rice grain development, and has important scientific research and application values.

The invention belongs to the field of veterinary biological products, and particularly relates to a chicken infectious laryngotracheitis recombinant subunit vaccine as well as a preparation method and application thereof. A core antigen of the vaccine is a recombinant gB trimer glycoprotein (gB-Trimer) modified by genetic engineering, and the protein successfully locks a prefusion conformation with the strongest immunogenicity of the gB protein through strategies of truncation, trimerization motif splicing, dual-stability mutation and the like. The vaccine prepared by the invention can stimulate rapid and lasting neutralizing antibody response, provide 100% clinical protection and effectively block replication and detoxification of the ILTV, has extremely high biological safety compared with a traditional live vaccine, completely eliminates risks of poison dispersion and enhancement, and provides a safe and efficient novel solution for prevention and control of the ILTV.

The invention discloses a lactobacillus brevis with broad-spectrum bacteriostatic activity and a separation method and application thereof, and belongs to the technical field of microorganisms, in particular to a lactobacillus brevis AW04 with broad-spectrum bacteriostatic activity, which is characterized in that the lactobacillus brevis AW04 is preserved in the China Center for Type Culture Collection, the lactobacillus brevis AW04 is preserved in the China Center for Type Culture Collection, the lactobacillus brevis AW04 is preserved in the China Center for Type Culture Collection, and the lactobacillus brevis AW04 is preserved in the China Center for Type Culture Collection. The address is Wuhan University Campus, Wuchang District, Wuhan City, Hubei Province; the postcode is 430072; the preservation number of the strain is CCTCC M 20241970; the preservation date is September 13, 2024. The strain provides a novel, safe and efficient strain resource for developing microecological preparations, feed additives or veterinary drugs for preventing and treating bacterial diarrhea of animals such as calves and the like, and has important value for reducing the use of antibiotics in the breeding industry and coping with bacterial drug resistance crisis. The strain can be produced on a large scale by using the existing fermentation technology and is convenient to apply.

The application discloses a novel fullerene hydrogel and a preparation method and application thereof. The fullerene hydrogel is formed by chemical cross-linking of a fullerene derivative shown in formula I and oxidized hyaluronic acid (oxHA). The fullerene-hyaluronic acid hydrogel material provided by the application has a porous framework, a large pore size and a cell loading potential.

This invention discloses a highly efficient chiral viral-like nanomedicine carrier for overcoming the gastrointestinal physiological barrier and its construction method, wherein the chiral viral-like nanomedicine carrier is a chiral viral-like mesoporous silica drug-loaded carrier. The construction method of the highly efficient chiral viral-like nanomedicine carrier for overcoming the gastrointestinal physiological barrier includes: using indomethacin as a model drug, and loading indomethacin IMC into a series of mesoporous silica spherical MSNs, viral mesoporous silica VSNs, and chiral viral-like mesoporous silica CVSNs. The chiral viral-like mesoporous silica of this invention has good degradability and biosafety. Its viral topology and chiral modification can enhance the surface and interfacial activity of the carrier and exhibit certain nanoscale chiral recognition capabilities, showing significant advantages in various processes of crossing the intestinal barrier. It can enhance its functionality as an oral drug carrier, has important research value and clinical translation prospects, and provides a reference for the surface and interfacial design of future drug carriers.

This invention discloses a nanoRNA delivery system and its application in the control of Sclerotinia sclerotinia disease, relating to the field of biotechnology. The preparation method of the nanoRNA delivery system includes the following steps: mixing chitosan, sucrose, and aspartic acid uniformly and then subjecting them to a hydrothermal reaction to obtain a quantum dot-chitosan degradation product complex; mixing the quantum dot-chitosan degradation product complex with double-stranded RNA to obtain the nanoRNA delivery system; the double-stranded RNA is used to silence Sclerotinia sclerotinia virulence-related transcription factor genes. The nanoRNA delivery system provided by this invention can effectively protect RNA and exhibits a very high inhibitory effect on Sclerotinia sclerotinia in plants, providing a novel technical solution for the green and precise control of Sclerotinia sclerotinia disease.

The present invention relates to the use of beta-hydroxy-beta-methylbutyric acid (HMB) or a pharmaceutically acceptable salt thereof as an inhibitor of Gasdermin D (GSDMD) in the manufacture of a medicament for the treatment of pyroptosis. HMB modulates pyroptosis in macrophages by blocking palmitoylation of GSDMD and has the potential to be a novel therapeutic agent for the treatment of inflammatory diseases driven by pyroptosis disorders.

This invention belongs to the field of antimicrobial peptide technology, and particularly relates to a broad-spectrum antimicrobial peptide with low hemolytic activity and its applications, as well as a broad-spectrum antibacterial drug. The antimicrobial peptide is named AY6, and its amino acid sequence is shown in SEQ ID NO.1. Antimicrobial peptide AY6 exhibits significant antibacterial effects against both Gram-positive and Gram-negative bacteria, with a bactericidal rate far exceeding that of traditional antibiotics, enabling highly effective responses to bacterial infections. AY6 has low hemolytic activity and good biocompatibility, making it suitable for medical anti-infective applications. The antimicrobial peptide provided in this application has a short sequence, is easy to synthesize chemically, can save on large-scale production costs, and has broad application prospects.

The invention relates to the technical field of microorganisms and the field of food, in particular to lactobacillus plantarum for inhibiting brown stain of soybean paste and application of lactobacillus plantarum. The lactobacillus plantarum is screened from traditional naturally-fermented peasant soybean paste in northeast China, and is preserved in China General Microbiological Culture Collection Center (CGMCC) on June 30, 2025, and the preservation number is CGMCC No.35048. The lactobacillus plantarum has an obvious browning inhibition effect and can be widely applied to fermented food production.

The application belongs to the field of medical materials, and particularly relates to a metal core enhanced double-barrier piezoelectric nano system and a preparation method and application thereof. The preparation method comprises the following steps: first, a core-shell structure of'metal@mesoporous titanium dioxide@mesoporous barium titanate' is prepared through a step-by-step reaction, and then the target nanoparticles are obtained through lipid wrapping. The system innovatively constructs a double-barrier structure, can self-trigger active oxygen under a physiological pressure of 4 mmHg, realizes endogenous pressure self-driven treatment of malignant ascites, has the advantages of low pressure, high catalytic efficiency, long-term structural stability and good biocompatibility, solves the problems that existing treatment methods are highly invasive and depend on exogenous stimulation, and provides a new safe and efficient technical scheme for the treatment of malignant ascites.

This invention discloses 5α-reductase degrading molecules, their preparation methods, and applications. Four 5α-reductase degrading molecules can induce proteasome-dependent degradation of 5α-reductase, achieving complete clearance of the enzyme protein rather than merely inhibiting its activity, thus obtaining a more durable therapeutic effect. Under equal-dose conditions, the 5α-reductase degrading molecules are more effective than the traditional inhibitor finasteride in treating benign prostatic hyperplasia (BPH). These four 5α-reductase degrading molecules can effectively degrade 5α-reductase protein and significantly inhibit the development of BPH, exhibiting good biocompatibility. This provides a new strategy and candidate drugs for the treatment of BPH, prostate cancer, androgenetic alopecia, acne, and other diseases related to 5α-reductase.

The invention relates to the technical field of medical preparations, in particular to moisturizing and repairing type artificial tear as well as a preparation method and application thereof. Comprising the following steps: preparing effective components including high-molecular-weight polydeoxyribonucleotide and hyaluronic acid or a salt thereof into a homogeneous-phase stable composite solution, sterilizing, filtering, and aseptically packaging, the artificial tear formed by selecting high-molecular-weight polydeoxyribonucleotide and high-molecular-weight sodium hyaluronate as effective components has a relatively good repairing effect on tissues, can form long-term moisturizing and lubrication on ocular surfaces, is suitable for treating xerophthalmia, repairing cornea, relieving inflammatory response and the like, and has a good application prospect. Important market values and clinical application prospects are realized.

This invention discloses an enzyme- and pH-responsive nucleic acid loading and delivery material and its preparation method. The material can be used for efficient loading and delivery of nucleic acid molecules. The preparation method uses amphiphilic zwitterionic monomers to improve the reverse emulsion polymerization system, enhancing polymerization at the two-phase interface and avoiding the extrusion effect of polymerization in the aqueous core on nucleic acid molecules, thereby improving the loading efficiency of nucleic acid molecules. Further preparation of cross-linking agents MP-CL and CB-CL, which can cleave in response to matrix metalloproteinase II or cathepsin B, endows the nanogel with the ability to respond to charge reversal in the tumor matrix and to release nucleic acid molecules from tumor cells. The acid-sensitive blocks on the amphiphilic monomers give the nanogel lysosomal escape capability. The delivery material can efficiently deliver nucleic acid molecules into cells and exhibits excellent stability and biosafety.

The invention provides lipid nanoparticles taking zinc phosphate as an inner core, a preparation method of the lipid nanoparticles and a medicine for treating aortic aneurysm, and relates to the technical field of biological medicines. The lipid nanoparticles provided by the invention comprise zinc phosphate nanoparticles, DOPA (Dioctyl-Phthalate Polyamide), ionizable cationic lipid, cholesterol and PEG (Polyethylene Glycol) lipid, the zinc phosphate nano-particles are inner cores of the lipid nano-particles. The lipid nanoparticles have excellent biocompatibility and safety and stable structure, and can improve the stability and delivery efficiency of nucleic acid (such as FBN1mRNA) as a carrier, thereby realizing effective treatment of diseases. According to the medicine for treating the aortic aneurysm, provided by the invention, accurate delivery of FBN1mRNA and expression in FBN1 cells can be realized, and angiogenesis and repair are promoted, so that accurate treatment of the aortic aneurysm is realized.

This invention relates to the field of medical biopolymer materials technology, specifically to an injectable hydrogel for kidney stone removal, its preparation method, and its application. The preparation materials include at least a precursor solution 1 and a precursor solution 2. Precursor solution 1 contains at least a polyethylene glycol derivative and a thickener, while precursor solution 2 contains at least a polyamino polymer. By optimizing the formulation ratio of the two-component precursor solutions, a hydrogel with strong conformability, good toughness, and viscosity is formed in situ in the kidney stone area. This encapsulates the kidney stone, facilitating its removal from the body and avoiding the safety hazards associated with small kidney stone fragments or conventional drug treatment.

The invention relates to the technical field of bioengineering, in particular to a targeting nanoparticle for treating acute respiratory distress syndrome as well as a preparation method and application of the targeting nanoparticle. Comprising the following steps: (1) combining MP peptide with DSPE-PEG2000-MAL through a maleimide-mercaptan reaction, dialyzing the obtained conjugate, washing, and freeze-drying, so as to obtain a DSPE-PEG2000-MP conjugate; and (2) mixing the conjugate, lipid, a pharmaceutical preparation and a solvent, removing the solvent to obtain a lipid film, hydrating the lipid film, and performing membrane extrusion to obtain the nanoparticles. The invention not only provides a novel efficient and safe ARDS treatment scheme, but also provides an innovative mode for the design of a nano-drug delivery system based on cell mediation. And due to the dual targeting capability, excellent anti-inflammatory efficiency and good biocompatibility, the nano-material has a wide prospect in clinical application.

The invention discloses an astaxanthin liposome-coating probiotic compound system based on an interface free radical quenching and bidirectional coupling mechanism and application of the astaxanthin liposome-coating probiotic compound system in oxidative stress protection, and belongs to the technical field of biological medicines and probiotic preparations. According to the preparation method, probiotics with an iron ion mediated sodium alginate-guar gum coating are constructed, and the probiotics and astaxanthin nano-liposomes form an interface protection layer in a hydrogen peroxide stress microenvironment. Wherein astaxanthin protects the key enzyme activity of a thallus energy metabolism pathway, and the thallus continuously consumes a hydrogen peroxide substrate in the environment through an enzyme system of the thallus. According to the composite system disclosed by the invention, under the condition of no chemical coupling, synergistic enhancement of antioxidant defense and thallus activity can be realized through physical blending, the survival rate and colonization ability of probiotics in gastrointestinal stress are remarkably improved, and an innovative solution is provided for targeted intervention of inflammatory bowel diseases and development of functional probiotic preparations.

Diabetes is a global metabolic disease characterized by chronic hyperglycemia, which can easily lead to serious complications such as retinopathy, kidney failure, cardiovascular disease, etc. Traditional hypoglycemic drugs are prone to drug resistance, gastrointestinal reactions, hypoglycemia and other side effects, and are difficult to repair islet function and reverse the course of the disease. The patent provides a plant lactobacillus with hypoglycemic effect, which was preserved in China General Microbiological Culture Collection Center on March 9, 2026, with the preservation number of CGMCC No. 37876. The patent also provides a probiotic chewing tablet prepared by using the strain and a preparation process thereof. The probiotic chewing tablet provided by the patent has good preservation stability, can safely improve sugar metabolism and protect islet function, and makes up for the defects of existing drugs and products, and has important application value and market prospect.

This invention discloses an octapeptide derived from soybean protein with the function of lowering blood pressure, blood sugar, and cholesterol, as well as its preparation and application, belonging to the field of small molecule peptide technology. The octapeptide sequence is YEGNWGPL, which can be obtained artificially or by targeted enzymatic hydrolysis of soybean protein isolate. Functional verification in a hyperlipidemia model shows that the octapeptide YEGNWGPL has the function of lowering blood lipids; functional verification in a hyperglycemia model shows that the octapeptide YEGNWGPL has the function of lowering blood sugar, with a significantly better effect than the drug metformin; functional verification in a hypertension model shows that the octapeptide YEGNWGPL has the function of lowering blood pressure, with a significantly better effect than the antihypertensive drug captopril; moreover, food-derived bioactive peptides have high biosafety, therefore, they can be applied to the development of related products for lowering blood pressure, blood sugar, and cholesterol or assisting in lowering blood pressure, blood sugar, and cholesterol, with good market prospects and application potential.

The application discloses Metrnl-a gene and application thereof in preparation of a DNA vaccine molecular adjuvant for grass carp hemorrhagic disease, and relates to the technical field of aquatic immunology and biological agents. The molecular adjuvant is that a grass carp Metrnl-a gene is constructed into a eukaryotic expression vector pcDNA3.1 to obtain a recombinant eukaryotic expression vector pcDNA3.1-Metrnl-a of the grass carp Metrnl-a. The pcDNA3.1-Metrnl-a plasmid and the pcDNA3.1-VP35 DNA vaccine can be stably expressed in the grass carp through muscle injection, significantly enhance the expression of immune-related genes and the antibody titer, significantly reduce the VP56 virus titer in the grass carp after challenge, and increase the survival rate of the grass carp after infection with grass carp reovirus by about 13.3%. The molecular adjuvant can effectively enhance the immune effect of the DNA vaccine of the grass carp and has a good application prospect.

The invention discloses a construction method and application of a chlamydomonas reinhardtii source high-sweetness induced protein variant engineering algal strain. The preparation method comprises the following steps: firstly, modifying and optimizing protein coding sequences of sweet taste induction proteins Miraculin and Neoculin, so as to obtain optimized gene sequences of CrMiraculin and CrNeoculin; the method comprises the following steps: firstly, preparing a Chlamydomonas reinhardtii strain, then cloning the Chlamydomonas reinhardtii strain into an expression vector pGM6, constructing a recombinant expression vector, introducing the recombinant expression vector into the Chlamydomonas reinhardtii wild strain, and screening by using a paromomycin resistance marker carried by the vector to obtain a transformed strain. The obtained engineering algal strain can stably inherit and efficiently express the target sweet induced protein, and the chlamydomonas reinhardtii algal powder rich in the CrMiraculin and CrNeoculin sweet induced protein is obtained by performing fermentation culture on the engineering algal strain. Finally, through protein purification and mixing with acidic substances, sour taste can be induced to be converted into sweet taste, so that the method has great application potential in the fields of foods, seasonings or health-care products.

This invention belongs to the field of biomedical materials technology, specifically relating to an oxidized hyaluronic acid / carboxymethyl chitosan hemostatic sponge and its preparation method. The preparation method includes: oxidizing hyaluronic acid with sodium periodate to obtain oxidized hyaluronic acid; preparing aqueous solutions of oxidized hyaluronic acid and carboxymethyl chitosan; mixing the two solutions and forming a hydrogel through a Schiff base reaction between aldehyde and amino groups; cryogelatinizing the hydrogel at low temperature and then freeze-drying it under vacuum to obtain an expandable hemostatic sponge with a three-dimensional interconnected porous structure. Upon contact with blood, the sponge of this invention rapidly absorbs water and expands, increasing in volume by more than three times, forming a tight physical seal. Simultaneously, it adsorbs and activates platelets to accelerate coagulation, achieving highly efficient hemostasis. This sponge exhibits excellent biocompatibility, is completely degradable in vivo, and the preparation process is mild and requires no toxic cross-linking agents. It can be used for rapid hemostasis of deep, irregular, and non-compressible bleeding wounds.

The invention discloses a drug-loaded nanoparticle as well as a preparation method and application thereof. The drug-loaded nanoparticle can be used for treating triple negative breast cancer, and specifically comprises a magnetic nanoparticle, an active component loaded in the magnetic nanoparticle, and an erythrocyte membrane coating the magnetic nanoparticle, wherein the active ingredients are selected from one or more of piperlongumine, polyphyllin II, erianin, pseudolaric acid, 6-gingerol, ginkgetin, solasonine, cucurbitacine B and lycorine. In practical application, the drug-loaded nanoparticles have good biological safety, long circulation capability and high tumor retention capability, and can generate efficient killing and treatment effects on triple-negative breast cancer by inducing cell apoptosis.

This invention discloses a nanodecoy receptor that blocks the IL-17 signaling pathway, including IL-17RA-CMVs carrying a fusion sequence of PDGFR-TMD and IL-17RA. This invention also provides a method for preparing the aforementioned nanodecoy receptor that blocks the IL-17 signaling pathway, comprising the following steps: S1. Using genetic engineering, IL-17RA and PDGFR-TMD are fused and designed, and a lentivirus carrying the IL-17RA and PDGFR-TMD fusion sequence is coated onto mammalian cells. A cell line stably expressing the IL-17RA and PDGFR-TMD fusion sequence is established in mammalian cells through lentivirus transfection; S2. The cell line from step S1 is taken, and cell membrane vesicles are prepared by ultrasonic disruption and permeabilization extrusion until the fusion sequence of IL-17RA carrying PDGFR-TMD is displayed at high density and correctly oriented on the outer surface of the cell membrane vesicles, forming IL-17RA-CMVs. The nano-decoy receptor of the present invention can efficiently and broadly block the interaction between IL-17 and IL-17RA, avoid such systemic side effects, and achieve treatment only through local minimally invasive delivery, thus solving the side effects problem caused by existing systemic drug administration.

The application discloses a glycosylated pH-responsive nanoliposome preparation and a preparation method and application thereof, and belongs to the field of medicines. A phospholipid bilayer of the liposome is composed of a pH-responsive lipid material, an amphiphilic polyethylene glycolated phospholipid derivative and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-glucose; and doxorubicin is used as a model chemotherapeutic drug and is loaded in a lipophilic region of the phospholipid bilayer. The nanoliposome can improve the drug accumulation efficiency in tumor tissues and prolong the in-vivo circulation time through glucose-mediated active tumor targeting, has pH-responsive drug release capacity, can release the chemotherapeutic drug under the micro-acidic condition of a tumor microenvironment, and thus has excellent anti-tumor effect. In addition, the nanoliposome has good biocompatibility and safety, and has good application prospect in the field of anti-tumor drugs.

This invention discloses a chitosan-Chlamydomonas reinhardtii protein composite carrier, its preparation method, and its application. The composite carrier has a triple network structure, comprising: a three-dimensional network backbone formed by cross-linking chitosan and sodium tripolyphosphate, constituting the first network; a functional enhancing phase, including Chlamydomonas reinhardtii protein, which is embedded and anchored in the three-dimensional network backbone through a first physical interaction, constituting the second network, thereby forming a chitosan-Chlamydomonas reinhardtii protein complex with an interpenetrating network structure; and a structure-directing agent, including a hydrophobic active substance, which self-assembles and embeds into the hydrophobic microregions of the chitosan-Chlamydomonas reinhardtii protein complex through a second physical interaction, constituting the third network. The composite carrier provided by this invention is prepared using electrospinning technology, achieving high loading capacity and high encapsulation efficiency, constructing a multi-layered antioxidant defense network, and can serve as a highly efficient and stable multifunctional carrier for the preparation of functional food delivery materials.

The present application relates to the technical field of microorganism, and especially relates to Enterococcus hirae C01, probiotic agent and application thereof.The present application provides the Enterococcus hirae C01, and the preservation number is CGMCC No.33994.The strain has broad-spectrum bacteriostatic activity, can inhibit Salmonella enteritidis, Salmonella pullorum and Salmonella typhimurium, has no hemolytic activity, has good stress resistance, can survive in gastrointestinal environment, and has high biological safety, and can be used for preventing and controlling mixed Salmonella infection in clinic.

The invention provides a drug carrier based on N-acetylglucosamine, a drug preparation and a preparation method. The drug carrier based on N-acetylglucosamine comprises N-acetylglucosamine and a cross-linking agent, the cross-linking agent is a compound with an aldehyde group or a ketone group, and the aldehyde group or the ketone group reacts with the deacetylated N-acetylglucosamine to generate one or more of a hydrazide bond, a hydrazone bond or an imine bond. The drug carrier based on N-acetylglucosamine shows remarkable advantages in the aspects of particle size distribution, drug loading capacity, encapsulation efficiency and cumulative drug release rate.

This invention provides a formulation and preparation method for an exosome-based skin medication. Taking the preparation of a 100g finished formulation as an example, it consists of active ingredients, a nanogel carrier, a composite stabilizer, a moisturizer, a pH adjuster, a preservative, and deionized water. By constructing a nanogel sustained-release system adapted to exosomes and a composite protection mechanism, the exosomes are stably and slowly released and efficiently absorbed on the skin surface within 7 days. This solves the problems of rapid release, low utilization rate, poor stability, and frequent reapplication required for exosome-based skin medications, thereby improving the skin care and treatment effects of exosomes.

The application belongs to the technical field of biological medicine, and more particularly relates to nanoparticles TK-PSBs / CBD@Met, a preparation method therefor and application thereof. The nanoparticles TK-PSBs / CBD@Met are nanoparticles formed by wrapping cannabidiol and metformin with thione-modified lung surfactant biomimetic liposomes. In vitro experiments have confirmed that the nanoparticles TK-PSBs / CBD@Met can effectively inhibit the fibrosis process of BEAS-2B cells induced by silicon dioxide. Animal experiments have shown that the nanoparticles TK-PSBs / CBD@Met can significantly improve the damage to the lung tissue structure and abnormal deposition of collagen caused by SiO2 exposure, and alleviate the pathological progression of silicosis fibrosis.